Autologous and allogeneic hematopoietic stem cell transplantation for Multiple Sclerosis: Perspective on mechanisms of action

Journal of Neuroimmunology

Volumn 197, Issue 2, 2008, Pages 89-98

  Van Wijmeersch, Bart ^a   Sprangers, Ben ^a   Dubois, Bénédicte ^a   Waer, Mark ^a   Billiau, An D ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Allogeneic; Autologous; Bone marrow transplantation; Hematopoietic stem cell transplantation; Multiple Sclerosis; Treatment

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE SCLEROSIS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 46649107295     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.04.030     Document Type: Review

References (89)

1. Ashton-Rickardt P.G., and Tonegawa S. A differential-avidity model for T-cell selection. Immunol. Today. 15 (1994) 362-366
2. Bettelli E., Baeten D., Jager A., Sobel R.A., and Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J. Clin. Invest. 116 (2006) 2393-2402
3. Binder T.A., Greiner D.L., Grunnet M., and Goldschneider I. Relative susceptibility of SJL/J and B10.S mice to experimental allergic encephalomyelitis (EAE) is determined by the ability of prethymic cells in bone marrow to develop into EAE effector T cells. J. Neuroimmunol. 42 (1993) 23-32
4. Blanco Y., Saiz A., Costa M., et al. Evolution of brain-derived neurotrophic factor levels after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurosci. Lett. 380 (2005) 122-126
5. Burt R.K., Burns W., Ruvolo P., et al. Syngeneic bone marrow transplantation eliminates V beta 8.2 T lymphocytes from the spinal cord of Lewis rats with experimental allergic encephalomyelitis. J. Neurosci. Res. 41 (1995) 526-531
6. Burt R.K., Cohen B.A., Russell E., et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 102 (2003) 2373-2378
7. Burt R.K., Oyama Y., Verda L., et al. Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. Arthritis. Rheum. 50 (2004) 2466-2470
8. Burt R.K., Padilla J., Begolka W.S., Canto M.C., and Miller S.D. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood 91 (1998) 2609-2616
9. Burt R.K., Traynor A.E., Cohen B., et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone. Marrow. Transplant. 21 (1998) 537-541
10. Burt R.K., Traynor A.E., Pope R., et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 92 (1998) 3505-3514
11. Carreras E., Saiz A., Marin P., et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 88 (2003) 306-314
12. Cassiani-Ingoni R., Muraro P.A., Magnus T., et al. Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J. Neuropathol. Exp. Neurol. 66 (2007) 637-649
13. Chaudhuri A., and Behan P.O. Multiple sclerosis is not an autoimmune disease. Arch. Neurol. 61 (2004) 1610-1612
14. Chen J.T., Collins D.L., Atkins H.L., Freedman M.S., Galal A., and Arnold D.L. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 66 (2006) 1935-1937
15. Confavreux C., and Vukusic S. Age at disability milestones in multiple sclerosis. Brain 129 (2006) 595-605
16. Confavreux C., and Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 129 (2006) 606-616
17. Douek D.C., Vescio R.A., Betts M.R., et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 355 (2000) 1875-1881
18. Dyment D.A., Willer C.J., Scott B., et al. Genetic susceptibility to MS: a second stage analysis in Canadian MS families. Neurogenetics 3 (2001) 145-151
19. Ebers G.C., Bulman D.E., Sadovnick A.D., et al. A population-based study of multiple sclerosis in twins. N. Engl. J. Med. 315 (1986) 1638-1642
20. European Study Group. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 352 (1998) 1491-1497
21. Fassas A., Anagnostopoulos A., Kazis A., et al. Autologous stem cell transplantation in progressive multiple sclerosis- an interim analysis of efficacy. J. Clin. Immunol. 20 (2000) 24-30
22. Fassas A., Anagnostopoulos A., Kazis A., et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone. Marrow. Transplant. 20 (1997) 631-638
23. Fassas A., Passweg J.R., Anagnostopoulos A., et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J. Neurol. 249 (2002) 1088-1097
24. Guillaume T., Rubinstein D.B., and Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 92 (1998) 1471-1490
25. Hartung H.P., Gonsette R., Konig N., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360 (2002) 2018-2025
26. Healey K.M., Pavletic S.Z., Al Omaishi J., et al. Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantation. Mult. Scler. 10 (2004) 284-289
27. Herrmann M.M., Gaertner S., Stadelmann C., et al. Tolerance induction by bone marrow transplantation in a multiple sclerosis model. Blood 106 (2005) 1875-1883
28. Hug A., Korporal M., Schroder I., et al. Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. J. Immunol. 171 (2003) 432-437
29. Inglese M., Mancardi G.L., Pagani E., et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J. Neurol. Neurosurg. Psychiatry. 75 (2004) 643-644
30. Jang E., Kim H.R., Cho S.H., et al. Prevention of spontaneous arthritis by inhibiting homeostatic expansion of autoreactive CD4+ T cells in the K/BxN mouse model. Arthritis. Rheum. 54 (2006) 492-498
31. Jeffery D.R. Failure of allogeneic bone marrow transplantation to arrest disease activity in multiple sclerosis. Mult. Scler. (2007)
32. Jones R.E., Bourdette D.N., Whitham R.H., Offner H., and Vandenbark A.A. Induction of experimental autoimmune encephalomyelitis in severe combined immunodeficient mice reconstituted with allogeneic or xenogeneic hematopoietic cells. J. Immunol. 150 (1993) 4620-4629
33. Karussis D., Vourka-Karussis U., Mizrachi-Koll R., and Abramsky O. Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation. Mult. Scler. 5 (1999) 17-21
34. Karussis D.M., Slavin S., Ben Nun A., et al. Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. J. Neuroimmunol. 39 (1992) 201-210
35. Karussis D.M., Slavin S., Lehmann D., Mizrachi-Koll R., Abramsky O., and Ben Nun A. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J. Immunol. 148 (1992) 1693-1698
36. Karussis D.M., Vourka-Karussis U., Lehmann D., et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J. Clin. Invest. 92 (1993) 765-772
37. Khorshid O., Hosing C., Bibawi S., et al. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J. Rheumatol. 31 (2004) 2513-2516
38. Kieper W.C., Troy A., Burghardt J.T., et al. Recent immune status determines the source of antigens that drive homeostatic T cell expansion. J. Immunol. 174 (2005) 3158-3163
39. Kohm A.P., Carpentier P.A., Anger H.A., and Miller S.D. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169 (2002) 4712-4716
40. Kozak T., Havrdova E., Pit'ha J., et al. Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. Transplant. Proc. 33 (2001) 2179-2181
41. Kozak T., Havrdova E., Pit'ha J., et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone. Marrow. Transplant. 25 (2000) 525-531
42. Krishnamoorthy G., Lassmann H., Wekerle H., and Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest. 116 (2006) 2385-2392
43. La Nasa G., Littera R., Cocco E., Battistini L., Marrosu M.G., and Contu L. Allogeneic hematopoietic stem cell transplantation in a patient affected by large granular lymphocyte leukemia and multiple sclerosis. Ann. Hematol. 83 (2004) 403-405
44. Lassmann H. Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain. Pathol. 15 (2005) 217-222
45. Lu Q., Lu L., Niu X., Guo Y., Parino G.R., and Liu D. Non-myeloablative allogeneic stem cell transplant in a patient with refractory systemic lupus erythematosus. Bone. Marrow. Transplant. 37 (2006) 979-981
46. Mancardi G.L., Saccardi R., Filippi M., et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57 (2001) 62-68
47. Mandalfino P., Rice G., Smith A., Klein J.L., Rystedt L., and Ebers G.C. Bone marrow transplantation in multiple sclerosis. J. Neurol. 247 (2000) 691-695
48. McAllister L.D., Beatty P.G., and Rose J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone. Marrow. Transplant. 19 (1997) 395-397
49. Metz I., Lucchinetti C.F., Openshaw H., et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 130 Pt 5 (2007) 1254-1262
50. Miller D.H., Molyneux P.D., Barker G.J., MacManus D.G., Moseley I.F., and Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann. Neurol. 46 (1999) 850-859
51. Morton J.I., and Siegel B.V. Transplantation of autoimmune potential. I. Development of antinuclear antibodies in H-2 histocompatible recipients of bone marrow from New Zealand Black mice. Proc. Natl. Acad. Sci. U. S. A. 71 (1974) 2162-2165
52. Muraro P.A., and Douek D.C. Renewing the T cell repertoire to arrest autoimmune aggression. Trends. Immunol. 27 (2006) 61-67
53. Muraro P.A., Douek D.C., Packer A., et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J. Exp. Med. 201 (2005) 805-816
54. Nash R.A., Bowen J.D., McSweeney P.A., et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102 (2003) 2364-2372
55. Nash R.A., Dansey R., Storek J., et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol. Blood. Marrow. Transplant. 9 (2003) 583-591
56. Navikas V., and Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J. Neurosci. Res. 45 (1996) 322-333
57. Ni X.S., Ouyang J., Zhu W.H., Wang C., and Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin. Transplant. 20 (2006) 485-489
58. Noseworthy J.H. Management of multiple sclerosis: current trials and future options. Curr. Opin. Neurol. 16 (2003) 289-297
59. Openshaw H., Lund B.T., Kashyap A., et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol. Blood. Marrow. Transplant. 6 (2000) 563-575
60. Oyama Y., Cohen B., Traynor A., Brush M., Rodriguez J., and Burt R.K. Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone. Marrow. Transplant. 29 (2002) 81-85
61. Pelfrey C.M., Waxman F.J., and Whitacre C.C. Genetic resistance in experimental autoimmune encephalomyelitis. I. Analysis of the mechanism of LeR resistance using radiation chimeras. Cell. Immunol. 122 (1989) 504-516
62. Polman C.H., O'Connor P.W., Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 899-910
63. Porrata L.F., Litzow M.R., and Markovic S.N. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo. Clin. Proc. 76 (2001) 407-412
64. Reimer P., Kunzmann V., Wilhelm M., et al. Cellular and humoral immune reconstitution after autologous peripheral blood stem cell transplantation (PBSCT). Ann. Hematol. 82 (2003) 263-270
65. Ridgway W.M., Fasso M., and Fathman C.G. A new look at MHC and autoimmune disease. Science 284 (1999) 749-751
66. Rocca M.A., Mondria T., Valsasina P., et al. A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis. AJNR. Am. J. Neuroradiol. 28 (2007) 1659-1661
67. Roccatagliata L., Rocca M.A., Valsasina P., et al. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Multiple. Sclerosis. 13 (2007) 1068-1070
68. Saccardi R., Kozak T., Bocelli-Tyndall C., et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult. Scler. 12 (2006) 814-823
69. Saccardi R., Mancardi G.L., Solari A., et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105 (2005) 2601-2607
70. Sadovnick A.D., Armstrong H., Rice G.P., et al. A population-based study of multiple sclerosis in twins: update. Ann. Neurol. 33 (1993) 281-285
71. Saiz A., Blanco Y., Carreras E., et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology 62 (2004) 282-284
72. Saiz A., Carreras E., Berenguer J., et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 56 (2001) 1084-1089
73. Samijn J.P., Te Boekhorst P.A., Mondria T., et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 77 (2006) 46-50
74. Schmidt D., Verdaguer J., Averill N., and Santamaria P. A mechanism for the major histocompatibility complex-linked resistance to autoimmunity. J. Exp. Med. 186 (1997) 1059-1075
75. Shapiro E., Krivit W., Lockman L., et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 356 (2000) 713-718
76. Singh R.K., Varney M.L., Buyukberber S., et al. Fas-FasL-mediated CD4+ T-cell apoptosis following stem cell transplantation. Cancer. Res. 59 (1999) 3107-3111
77. Sprangers B., Van Wijmeersch B., Fevery S., Waer M., and Billiau A.D. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. Nat. Clin. Pract. Oncol. 4 (2007) 404-414
78. Su L., Xu J., Ji B.X., et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int. J. Hematol. 84 (2006) 276-281
79. Sun W., Popat U., Hutton G., et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain 127 (2004) 996-1008
80. Sykes M. Mixed chimerism and transplant tolerance. Immunity 14 (2001) 417-424
81. Tauro S., and Mahendra P. Resolution of sarcoidosis after allogeneic bone marrow transplantation with donor lymphocyte infusions. Bone. Marrow. Transplant. 27 (2001) 757-759
82. van Gelder M., Kinwel-Bohre E.P., and van Bekkum D.W. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone. Marrow. Transplant. 11 (1993) 233-241
83. van Gelder M., Mulder A.H., and van Bekkum D.W. Treatment of relapsing experimental autoimmune encephalomyelitis with largely MHC-matched allogeneic bone marrow transplantation. Transplantation 62 (1996) 810-818
84. van Gelder M., and van Bekkum D.W. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone. Marrow. Transplant. 16 (1995) 343-351
85. van Gelder M., and van Bekkum D.W. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone. Marrow. Transplant. 18 (1996) 1029-1034
86. Van Wijmeersch B., Sprangers B., Rutgeerts O., et al. Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect. Biol. Blood. Marrow. Transplant. 13 (2007) 627-637
87. Venken K., Hellings N., Hensen K., et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J. Neurosci. Res. 83 (2006) 1432-1446
88. Viglietta V., Baecher-Allan C., Weiner H.L., and Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199 (2004) 971-979
89. Xu J., Ji B.X., Su L., Dong H.Q., Sun X.J., and Liu C.Y. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin. Med. J. (Engl.). 119 (2006) 1851-1855